Top Markets
Coin of the day
Pharma Mar, S.A. Pharma Mar, S.A.

Pharma Mar, S.A.

PHM
Rangering i aksjer #7110
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and... Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Aksjekurs
$99.16
Sist synkronisert: 2026-08-27
Markedsverdi
$1.72B
Endring (1 dag)
0.00%
Endring (1 år)
2.52%
Land
ES
Handel Pharma Mar, S.A. (PHM)

Kategori

P/B-forhold for Pharma Mar, S.A. (PHM)
P/B-forhold per 2026 TTM: 0
Ifølge Pharma Mar, S.A. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Pharma Mar, S.A. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH